Yeast β-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-Kinase pathway

Journal of Immunology

Volumn 177, Issue 3, 2006, Pages 1661-1669

  Li, Bing ^a   Allendorf, Daniel J ^a   Hansen, Richard ^a   Marroquin, Jose ^a   Ding, Chuanlin ^a   Cramer, Daniel E ^a   Yan, Jun ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3B; EPITOPE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CONFOCAL MICROSCOPY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SURVIVAL; TUMOR; TUMOR CELL;

EID: 33746190826     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.3.1661     Document Type: Article

References (42)

1. Ross, J. S., D. P. Schenkein, R. Pietrusko, M. Rolfe, G. P. Linette, J. Stec, N. E. Stagliano, G. S. Ginsburg, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi. 2004. Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 122: 598-609.
2. Gelderman, K. A., S. Tomlinson, G. D. Ross, and A. Gorter. 2004. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25: 158-154.
3. Di Luzio, N. R., R. McNamee, W. I. Browder, and D. Williams. 1978. Glucan: inhibition of tumor growth and enhancement of survival in four syngeneic murine tumor models. Cancer Treat. Rep. 62: 1857-1866.
4. Kimura, Y., H. Tojima, S. Fukase, and K. Takeda. 1994. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol. Suppl. 511: 192-195.
5. Matsuoka, H., Y. Seo, H. Wakasugi, T. Saito, and H. Tomoda. 1997. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 17: 2751-2755.
6. Yan, J., D. J. Allendorf, and B. Brandley. 2005. Yeast whole glucan particle (WGP) β-glucan in conjunction with antitumor monoclonal antibodies to treat cancer. Exp. Opin. Biol. Ther. 5: 691-702.
7. Gawronski, M., J. T. Park, A. S. Magee, and H. Conrad. 1999. Microfibrillar structure of PGG-glucan in aqueous solution as triple-helix aggregates by small angle x-ray scattering. Biopolymers 50: 569-578.
8. Williams, D. L., H. A. Pretus, R. B. McNamee, E. L. Jones, H. E. Ensley, I. W. Browder, and N. R. Di Luzio. 1991. Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology 22: 139-155.
9. Patchen, M. L., T. Vaudrain, H. Correira, T. Martin, and D. Reese. 1998. In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Exp. Hematol. 26: 1247-1254.
10. Yan, J., V. Vetvicka, Y. Xia, A. Coxon, M. C. Carroll, T. N. Mayadas, and G. D. Ross. 1999. β-Glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol. 163: 3045-3052.
11. Hong, F., R. D. Hansen, J. Yan, D. J. Allendorf, J. T. Baran, G. R. Ostroff, and G. D. Ross. 2003. β-Glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 63: 9023-9031.
12. Hong, F., J. Yan, J. T. Baran, D. J. Allendorf, R. D. Hansen, G. R. Ostroff, P. X. Xing, N. K. Cheung, and G. D. Ross. 2004. Mechanism by which orally administered β-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 173: 797-806.
13. 4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and β-glucan. J. Immunol. 174: 7050-7056.
14. Thornton, B. P., V. Vetvicka, M. Pitman, R. C. Goldman, and G. D. Ross. 1996. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156: 1235-1246.
15. Van, J., V. Vetvicka, Y. Xia, M. Hanikyrova, T. N. Mayadas, and G. D. Ross. 2000. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble β-glucan. Immunopharmacology 46: 39-54.
16. Cheung, N. K., and S. Modak. 2002. Oral (1→3),(1→4)-β-D- glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res. 8: 1217-1223.
17. Cheung, N. K., S. Modak, A. Vickers, and B. Knuckles. 2002. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother. 51: 557-564.
18. Modak, S., G. Koehne, A. Vickers, R. J. O'Reilly, and N. K. Cheung. 2005. Rituximab therapy of lymphoma is enhanced by orally administered (1→3),(1→4)-D-β-glucan. Leuk. Res. 29: 679-683.
19. Solly, K., X. Wang, X. Xu, B. Strulovici, and W. Zheng. 2004. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev. Technol. 2: 363-372.
20. An, H., H. Xu, M. Zhang, J. Zhou, T. Feng, C. Qian, R. Qi, and X. Cao. 2005. Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism. Blood 105: 4685-4692.
21. Ross, G. D., J. A. Cain, B. L. Myones, S. L. Newman, and P. J. Lachmann. 1987. Specificity of membrane complement receptor type three (CR3) for β-glucans. Complement 4: 61-74.
22. Oxvig, C., C. Lu, and T. A. Springer. 1999. Conformational changes in tertiary structure near the ligand binding site of an integrin I domain. Proc. Natl. Acad. Sci. USA 96: 2215-2220.
23. Naccache, P. H., N. Jean, N. W. Liao, J. M. Bator, S. R. McColl, and P. Kubes. 1994. Regulation of stimulated integrin surface expression in human neutrophils by tyrosine phosphorylation. Blood 84: 616-624.
24. 2+ binding epitope on leukocyte integrin α subunits. EMBO J. 8: 3759-3765.
25. Vetvicka, V., B. P. Thornton, and G. D. Ross. 1996. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98: 50-61.
26. Vetvicka, V., B. P. Thornton, T. J. Wieman, and G. D. Ross. 1997. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J. Immunol. 159: 599-605.
27. Berton, G., A. Mocsai, and C. A. Lowell. 2005. Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol. 26: 208-214.
28. Mocsai, A., M. Zhou, F. Meng, V. L. Tybulewicz, and C. A. Lowell. 2002. Syk is required for integrin signaling in neutrophils. Immunity 16: 547-558.
29. Deane, J. A., and D. A. Fruman. 2004. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 22: 563-598.
30. Koyasu, S. 2003. The role of P13K in immune cells. Nat. Immunol. 4: 313-319.
31. Liu, J., Z. Liu, S. Chuai, and X. Shen. 2003. Phospholipase C and phosphatidyl-inositol 3-kinase signaling are involved in the exogenous arachidonic acid-stimulated respiratory burst in human neutrophils. J. Leukocyte Biol. 74: 428-437.
32. Moon, K. D., C. B. Post, D. L. Durden, Q. Zhou, P. De, M. L. Harrison, and R. L. Geahlen. 2005. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J. Biol. Chem. 280: 1543-1551.
33. Vetvicka, V., M. Hanikyrova, J. Vetvickova, and G. D. Ross. 1999. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumor target cell MHC class I molecules. Clin. Exp. Immunol. 115: 229-235.
34. Xia, Y., V. Vetvicka, J. Van, M. Hanikyrova, T. Mayadas, and G. D. Ross. 1999. The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 162: 2281-2290.
35. Brown, G. D., P. R. Taylor, D. M. Reid, J. A. Willment, D. L. Williams, L. Martinez-Pomares, S. Y. Wong, and S. Gordon. 2002. Dectin-1 is a major β-glucan receptor on macrophages. J. Exp. Med. 196: 407-412.
36. Taylor, P. R., G. D. Brown, D. M. Reid, J. A. Willment, L. Martinez-Pomares, S. Gordon, and S. Y. Wong. 2002. The β-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J. Immunol. 169: 3876-3882.
37. Taylor, P. R., L. Martinez-Pomares, M. Stacey, H. H. Lin, G. D. Brown, and S. Gordon. 2005. Macrophage receptors and immune recognition. Annu. Rev. Immunol. 23: 901-944.
38. Diamond, M. S., and T. A. Springer. 1993. A subpopulation of Mac-1 (CD11b/ CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J. Cell Biol. 120: 545-556.
39. Xia, Y., and G. D. Ross. 1999. Generation of recombinant fragments of CD11b expressing the functional β-glucan-binding lectin site of CR3 (CD11b/CD18). J. Immunol. 162: 7285-7293.
40. Klein, J. B., M. J. Rane, J. A. Scherzer, P. Y. Coxon, R. Kettritz, J. M. Mathiesen, A. Buridi, and K. R. McLeish. 2000. Granulocyte-macrophage colony-stimulating factor delays neutrophil constitutive apoptosis through phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways. J. Immunol. 164: 4286-4291.
41. Ross, G. D., and V. Vetvicka. 1993. CR3 (CD11b.CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin. Exp. Immunol. 92: 181-184.
42. Williams, D. L., C. Li, T. Ha, T. Ozment-Skelton, J. H. Kalbfleisch, J. Preiszner, L. Brooks, K. Breuel, and J. B. Schweitzer. 2004. Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J. Immunol. 172: 449-456.